Red clover appears on a growing number of cosmetic ingredient lists, often accompanied by confident claims about what it can do for skin. The evidence calls for a more measured view. Red clover is a recognised cosmetic ingredient and is used in skincare formulations, but the clinical evidence for its effects on human skin remains limited. There is research behind it, but considerably less than many marketing claims suggest.
That distinction matters. It is useful to separate what has been demonstrated from what is biologically plausible and from what has simply become common marketing language. This article looks at the evidence with those differences in mind.
What red clover is actually registered as
The European Commission maintains CosIng, an inventory of substances used in cosmetic products. It records an ingredient's INCI name, identifying information and declared cosmetic functions. Two red clover entries are relevant here.
Trifolium Pratense Leaf Extract (CosIng no. 59840, CAS 85085-25-2, EC 285-356-7) is described as an extract of the leaves of Trifolium pratense L. Its registered functions are antioxidant and skin conditioning.
Trifolium Pratense Flower Extract (CosIng no. 59842, with the same CAS and EC numbers) is described as an extract of the flowers. Its registered functions are astringent and fragrance.
The distinction between leaf and flower matters because the two entries carry different declared cosmetic functions. We discuss this in more detail in our guide on how to choose a red clover product.
It is equally important to understand what CosIng does not mean. CosIng is an inventory, not an approval list. An ingredient appearing in the database means that it is catalogued with declared cosmetic functions. It does not mean that a regulator has evaluated or endorsed a particular skincare benefit.
For that reason, describing red clover as "EU approved" is inaccurate. A more precise statement is that the ingredient is registered in the EU's CosIng cosmetic ingredient database.
Neither of the two red clover entries discussed above carries a restriction or annex listing in the CosIng records referenced here. From that regulatory perspective, they sit within the ordinary cosmetic ingredient inventory.
Why formulators use it
Red clover is a notable plant source of isoflavones, particularly biochanin A and formononetin. These compounds are metabolically related to genistein and daidzein. Reviews of the Trifolium genus also describe flavonoids, clovamides and other phenolic compounds in the plant.
Isoflavones are commonly described as phytoestrogens because their molecular structure allows them to interact weakly with estrogen receptors. That description needs context. These compounds are not hormones and should not be treated as equivalent to hormone therapy.
The relationship is relevant to skin research because skin is an estrogen-responsive organ. Estrogen receptors are present in the epidermis, dermal fibroblasts and hair follicles. Dermatological research also documents changes in skin around menopause, including reductions in collagen density and elasticity and an increase in dryness as estrogen levels decline.
What remains uncertain is whether applying red clover-derived compounds topically produces a meaningful version of those biological effects in human skin. The mechanism is plausible, but a plausible mechanism is not the same as clinical evidence.
Isoflavones also show antioxidant activity in laboratory assays. This is a more modest rationale for cosmetic use and is consistent with the antioxidant function registered for Trifolium Pratense Leaf Extract in CosIng.
What the evidence actually looks like
What exists
There is a body of laboratory research on red clover isoflavones. Studies have examined their effects in cell-based models, including fibroblast behaviour, enzymes involved in connective tissue turnover and antioxidant activity.
Animal studies also exist, including work in ovariectomised rodents, which are commonly used as models of estrogen-deprived tissue. Some of these studies have reported changes in skin collagen content.
Human evidence is more limited. One frequently cited study was a randomised, placebo-controlled crossover trial involving 109 postmenopausal women. Participants took 80 mg of red clover extract or placebo daily for 90 days before crossing over to the other treatment. During the red clover phase, participants reported improvements in the subjective condition of their skin and scalp hair.
What does not exist
The limitations are important. As of the literature reviewed for this article, we could not identify a published systematic review or meta-analysis dedicated specifically to red clover and skin outcomes.
Systematic reviews do exist for other uses of red clover, including menopausal symptoms, where the evidence base is substantially larger. The skin literature is much smaller.
The available human evidence also relies heavily on subjective endpoints, such as participants rating their own skin on visual analogue scales.
Self-assessment is a valid way to measure perceived changes, but it is different from objective methods such as corneometry, cutometry, biopsy or imaging of dermal structure. Subjective outcomes can also be more sensitive to expectation effects.
Another important limitation is that most of the human research involves oral red clover rather than topical cosmetics. The crossover trial described above studied capsules, not a cream.
Evidence-based herbal references, including the Phytopharmacy monograph on red clover, likewise discuss the plant primarily as an orally used herbal product. They should not be treated as direct evidence for topical cosmetic performance.
What that adds up to
The current picture is a biologically plausible mechanism supported by laboratory and animal research, together with a relatively small amount of human evidence, much of it based on oral supplementation and subjective outcomes.
That is better described as an early evidence base than as proof of a clinically established skincare active.
Why soy research does not transfer
Searching the broader literature on isoflavones and skin produces far more studies than searching specifically for red clover. A large proportion of that research involves soy.
Soy and red clover are both isoflavone-rich legumes, but their chemical profiles are different.
Soy is dominated by genistein and daidzein and their glycosides. Red clover is dominated by biochanin A and formononetin. Biochanin A and formononetin are methylated relatives of genistein and daidzein, and those structural differences affect metabolism and receptor binding.
A result obtained with soy isoflavones is therefore evidence about the preparation that was studied. It should not automatically be presented as evidence for red clover.
When evaluating a claim about red clover and skin, it is worth checking the original citation to see which plant and which preparation were actually used.
Topical and oral are two different questions
A major source of confusion is treating oral and topical use as though they were equivalent.
An oral isoflavone product passes through the digestive system, is metabolised and produces systemic exposure. This is the route used in most of the clinical red clover literature and is also the route associated with the main safety considerations.
A topical cosmetic follows a different route. It is applied directly to the skin, and any movement of isoflavones through the stratum corneum depends on factors such as molecular size, solubility and the formulation carrying them.
Published data specifically measuring penetration of red clover isoflavones from finished cosmetic formulations remains sparse. For that reason, precise claims about how much red clover is absorbed from a cream should be treated cautiously unless they are supported by formulation-specific evidence.
We explore the distinction in more detail in cream or capsule, and what actually changes between them.
What is realistic to expect
A red clover skincare product is still a cosmetic. Under EU and Turkish cosmetic frameworks, cosmetics are intended to clean, perfume, protect, maintain the condition of or change the appearance of external parts of the body. They are not medicines and should not be presented as treating disease or regulating physiological functions.
A realistic view of red clover in skincare is therefore relatively straightforward. It is a botanical ingredient that can contribute antioxidant and skin-conditioning functions within a broader formulation.
The visible day-to-day performance of a moisturiser also depends heavily on the rest of the formula, including humectants, emollients and occlusive ingredients. Red clover should be considered as one part of that system rather than as a standalone treatment.
This is the approach behind our own red clover skin care range.
Red clover skincare should not be treated as a substitute for sun protection or dermatological treatment, and the current literature does not provide a randomised topical trial with objective skin measurements that would justify presenting it that way.
If you want a broader overview of the plant, see our full guide to red clover for skin, hair and health. Our red clover ingredient page also explains how we source and work with the plant.
Who should be cautious
Topical cosmetic use of red clover extract is generally well tolerated, and neither of the CosIng entries discussed above carries a listed restriction. As with other botanical ingredients, patch testing may be sensible for people with reactive skin, and anyone with a known legume allergy should review the full ingredient list carefully.
The more significant cautions relate to oral red clover because oral supplementation produces systemic exposure.
Red clover supplements are generally not advised during pregnancy or breastfeeding. Medical advice is also appropriate for anyone with a hormone-sensitive condition, including a history of breast, uterine or ovarian cancer, endometriosis or uterine fibroids, and for people taking anticoagulants, hormonal contraceptives or hormone therapy.
We cover these issues in more detail in our article on red clover side effects and interactions.
Frequently asked questions
Is red clover proven to work on skin?
Not in the sense of having a large, settled clinical evidence base.
There is a plausible biological mechanism, together with laboratory and animal research, but human evidence remains limited. The available studies rely largely on subjective self-assessment and mostly involve oral supplements rather than topical products.
We could not identify a systematic review or meta-analysis dedicated specifically to red clover and skin. The evidence is better described as early-stage than conclusive.
Is red clover extract EU approved for cosmetics?
No. "EU approved" is not an accurate description in this context.
Trifolium Pratense Leaf Extract and Trifolium Pratense Flower Extract are listed in the EU CosIng cosmetic ingredient database with declared cosmetic functions. CosIng is an inventory, not an approval or endorsement system.
Why do so many articles say red clover is proven for skin?
One reason is that research on soy isoflavones is sometimes presented as though it applies directly to red clover.
The two plants have different dominant isoflavones. Soy is rich in genistein and daidzein, while red clover is dominated by biochanin A and formononetin.
Because the chemical profiles differ, findings from soy cannot automatically be transferred to red clover.
Does red clover work better in a cream or a capsule?
They should not be compared as stronger and weaker versions of the same product.
A capsule produces systemic exposure and is the form used in most clinical red clover studies. A cream is a topical cosmetic applied to the skin and follows a different route of exposure.
The two forms serve different purposes and have different safety considerations.
Is red clover in skincare safe?
Topical cosmetic use is generally well tolerated, and the referenced CosIng entries carry no listed restriction. People with reactive skin may still wish to patch test a new product.
The commonly discussed cautions involving pregnancy, breastfeeding, hormone-sensitive conditions and anticoagulant medication relate mainly to oral red clover supplements rather than topical cosmetics.
This article is for general information and education. It is not medical advice, and Minerva108 cosmetic products are not intended to diagnose, treat, cure or prevent any disease. If you are pregnant, breastfeeding, taking medication or managing a health condition, speak with a healthcare professional before using red clover supplements.
References
- European Commission. CosIng: Cosmetic Ingredient Database: Trifolium Pratense Leaf Extract, substance no. 59840 (CAS 85085-25-2, EC 285-356-7); functions: antioxidant, skin conditioning. ec.europa.eu
- European Commission. CosIng: Cosmetic Ingredient Database: Trifolium Pratense Flower Extract, substance no. 59842 (CAS 85085-25-2, EC 285-356-7); functions: astringent, fragrance. ec.europa.eu
- Edwards SE, da Costa Rocha I, Williamson EM, Heinrich M. Phytopharmacy: An Evidence-Based Guide to Herbal Medicinal Products. Wiley-Blackwell, 2015 (red clover monograph). ISBN 978-1-118-54356-6. wiley.com
- Kołodziejczyk-Czepas J. Trifolium species – the latest findings on chemical profile, ethnomedicinal use and pharmacological properties. Journal of Pharmacy and Pharmacology, 2016;68(7):845–861. doi:10.1111/jphp.12568. doi.org
- Lipovac M, Chedraui P, Gruenhut C, et al. Effect of red clover isoflavones over skin, appendages, and mucosal status in postmenopausal women. Obstetrics and Gynecology International, 2011;2011:949302. doi:10.1155/2011/949302. doi.org